Invivyd Inc. (IVVD)
0.47
-0.04 (-8.56%)
At close: Apr 16, 2025, 3:59 PM
0.48
1.64%
After-hours: Apr 16, 2025, 04:58 PM EDT
-8.56% (1D)
| Bid | 0.47 |
| Market Cap | 56.72M |
| Revenue (ttm) | 25.38M |
| Net Income (ttm) | -169.93M |
| EPS (ttm) | -1.43 |
| PE Ratio (ttm) | -0.33 |
| Forward PE | 0.59 |
| Analyst | Buy |
| Ask | 0.51 |
| Volume | 1,139,832 |
| Avg. Volume (20D) | 15,163,185 |
| Open | 0.50 |
| Previous Close | 0.51 |
| Day's Range | 0.46 - 0.51 |
| 52-Week Range | 0.35 - 2.75 |
| Beta | 0.41 |
About IVVD
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with A...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 6, 2021
Employees 99
Stock Exchange NASDAQ
Ticker Symbol IVVD
Website https://adagiotx.com
Analyst Forecast
According to 4 analyst ratings, the average rating for IVVD stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 1803.55% from the latest price.
Stock ForecastsNext Earnings Release
Invivyd Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+2.58%
Invivyd shares are trading higher after the compan...
Unlock content with
Pro Subscription
1 month ago
-29.94%
Invivyd shares are trading lower after the company announced the FDA has declined its request to expand its existing emergency use authorization of PEMGARDA.
